The Latest Breaking News from Mizuho Securities

Microsoft stock received a flurry of price-target hikes after announcing its artificial intelligence-powered Bing search engine.

After posting better-than-expected third-quarter results, DoorDash Inc (NYSE: DASH) received four price target changes from analysts.

Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal dihydroergotamine (DHE) for migraine. 

Electric vehicle company Rivian Automotive Inc (NASDAQ: RIVN) reported first-quarter production of 2,553 vehicles. The company delivered 1,227 vehicles in the first quarter and reported more than 90,000 net pre-orders of its Rivian R1 electric pickup truck.

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves toes back into the correct position.  RBC Capital Markets writes that although trends of pain reduction were observed in the 400 mg QID ACP-044 arm compared…

Shares of Okta Inc (NASDAQ: OKTA) have lost 42% over the past six months, while the company’s organic growth remains strong, according to Mizuho Securities.

On CNBC, Mizuho Securities analyst Vijay Rakesh said growth stocks have seen some headwinds in the recent period due to the prospects of rate hikes by the Federal Reserve.